Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery (Q58167278)

Nils B. Jørgensen

4

0 references

Kirstine N Bojsen-Møller

Kirstine N. Bojsen-Møller

2

0 references

Bolette Hartmann

Bolette Hartmann

8

0 references

Sten Madsbad

Sten Madsbad

10

0 references

Jens Juul Holst

Jens J. Holst

9

0 references

Carsten Dirksen

5

Carsten Dirksen

0 references

Flemming Bendtsen

6

Flemming Bendtsen

0 references

author name string

Signe Nielsen

3

0 references

Viggo B. Kristiansen

American Journal of Physiology - Endocrinology and Metabolism

7

0 references

publication date

April 2016

0 references

published in

0 references

volume

310

0 references

page(s)

E505-E514

0 references

issue

7

0 references

cites work

On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

ISEC: a program to calculate insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Stability of glucagon-like peptide 1 and glucagon in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00471.2015